Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com

StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a research report sent to investors on Saturday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Performance

Shares of LPCN opened at $4.69 on Friday. Lipocine has a one year low of $3.20 and a one year high of $11.79. The firm has a market capitalization of $25.09 million, a price-to-earnings ratio of -6.17 and a beta of 1.23. The stock’s fifty day moving average is $4.82 and its 200-day moving average is $4.89.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter. Analysts forecast that Lipocine will post -0.78 EPS for the current fiscal year.

Hedge Funds Weigh In On Lipocine

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP acquired a new position in Lipocine Inc. (NASDAQ:LPCN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned 0.22% of Lipocine as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.